ES2249309T3 - Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa. - Google Patents
Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.Info
- Publication number
- ES2249309T3 ES2249309T3 ES00980576T ES00980576T ES2249309T3 ES 2249309 T3 ES2249309 T3 ES 2249309T3 ES 00980576 T ES00980576 T ES 00980576T ES 00980576 T ES00980576 T ES 00980576T ES 2249309 T3 ES2249309 T3 ES 2249309T3
- Authority
- ES
- Spain
- Prior art keywords
- csbp
- compounds
- inhibitors
- kinasa
- dihidro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
Abstract
1-fenil-2-oxo-3,4-dihidro-6-fenilaminoquinazolina, o una sal farmacéuticamente aceptable de la misma.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16697299P | 1999-11-23 | 1999-11-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2249309T3 true ES2249309T3 (es) | 2006-04-01 |
Family
ID=22605414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES00980576T Expired - Lifetime ES2249309T3 (es) | 1999-11-23 | 2000-11-21 | Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa. |
Country Status (8)
Country | Link |
---|---|
US (1) | US6982270B1 (es) |
EP (1) | EP1233950B1 (es) |
JP (1) | JP2003528043A (es) |
AT (1) | ATE305787T1 (es) |
AU (1) | AU1782301A (es) |
DE (1) | DE60023025T2 (es) |
ES (1) | ES2249309T3 (es) |
WO (1) | WO2001038313A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2241675T3 (es) * | 1999-11-23 | 2005-11-01 | Smithkline Beecham Corporation | Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de cspb/p38 quinasa. |
EP1248624A4 (en) * | 1999-11-23 | 2003-01-22 | Smithkline Beecham Corp | 3,4-DIHYDRO- (1H) -CHIRAZOLINE-2-ONES AND THE USE THEREOF AS CSBP / P38 KINASE INHIBITORS |
AU2002248269A1 (en) * | 2000-10-19 | 2002-08-12 | Smithkline Beecham Corporation | Use of p38 inhibitors for the treatment of inflammation-enhanced cough |
AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
AU2002325026A1 (en) * | 2001-09-27 | 2003-04-07 | St. Jude Children's Research Hospital, Inc. | Use of neuraminidase inhibitors to prevent flu associated bacterial infections |
JP2005538066A (ja) | 2002-07-09 | 2005-12-15 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規な抗コリン作用薬及びp38キナーゼ阻害剤を用いた新規な医薬組成物 |
WO2004014869A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
WO2006137421A1 (ja) * | 2005-06-21 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | 局所投与剤 |
US20070231298A1 (en) * | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
ES2400695T3 (es) | 2006-07-17 | 2013-04-11 | Amgen Inc. | Derivados de quinazolina y piridopirimidina como inhibidores de la cinasa p38 |
US20100104536A1 (en) * | 2007-03-20 | 2010-04-29 | Indravadan Ambalal Modi | P38 inhibitors |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
AU2018346709A1 (en) | 2017-10-05 | 2020-04-16 | Fulcrum Therapeutics, Inc. | Use of p38 inhibitors to reduce expression of DUX4 |
GB201721793D0 (en) | 2017-12-22 | 2018-02-07 | Hvivo Services Ltd | Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2833779A (en) | 1956-10-29 | 1958-05-06 | American Cyanamid Co | Substituted pyrazoles |
US3707475A (en) | 1970-11-16 | 1972-12-26 | Pfizer | Antiinflammatory imidazoles |
US3940486A (en) | 1971-05-10 | 1976-02-24 | Ciba-Geigy Corporation | Imidazole derivatives in the treatment of pain |
US3929807A (en) | 1971-05-10 | 1975-12-30 | Ciba Geigy Corp | 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles |
US4058614A (en) | 1973-12-04 | 1977-11-15 | Merck & Co., Inc. | Substituted imidazole compounds and therapeutic compositions therewith |
US4199592A (en) | 1978-08-29 | 1980-04-22 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-2-nitroimidazoles |
GR75287B (es) | 1980-07-25 | 1984-07-13 | Ciba Geigy Ag | |
WO1983002613A1 (en) | 1981-07-20 | 1983-08-04 | Sallmann, Alfred | Trisubstituted oxazo compounds |
US4503065A (en) | 1982-08-03 | 1985-03-05 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl 1-2-halo imidazoles |
JPS60226882A (ja) | 1984-04-24 | 1985-11-12 | Nippon Zoki Pharmaceut Co Ltd | 新規ピリミドピリミジン誘導体 |
US4565875A (en) | 1984-06-27 | 1986-01-21 | Fmc Corporation | Imidazole plant growth regulators |
US4686231A (en) | 1985-12-12 | 1987-08-11 | Smithkline Beckman Corporation | Inhibition of 5-lipoxygenase products |
IL83467A0 (en) | 1986-08-15 | 1988-01-31 | Fujisawa Pharmaceutical Co | Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same |
JPH05508153A (ja) | 1990-06-12 | 1993-11-18 | スミスクライン・ビーチャム・コーポレイション | 5―リポキシゲナーゼ経路およびシクロオキシゲナーゼ経路で媒介される疾患の阻害 |
FR2665898B1 (fr) | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
IE913473A1 (en) | 1990-10-15 | 1992-04-22 | Fujisawa Pharmaceutical Co | Quinazoline derivatives and their preparation |
AU9169991A (en) | 1990-12-13 | 1992-07-08 | Smithkline Beecham Corporation | Novel csaids |
KR930703321A (ko) | 1990-12-13 | 1993-11-29 | 스튜어트 알. 슈터 | 신규한 사이토킨 억제성 소염 의약 |
WO1992012154A1 (en) | 1990-12-31 | 1992-07-23 | Fujisawa Pharmaceutical Co., Ltd. | Imidazotriazine derivatives |
US5656644A (en) | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
US5916891A (en) | 1992-01-13 | 1999-06-29 | Smithkline Beecham Corporation | Pyrimidinyl imidazoles |
US6008235A (en) | 1992-01-13 | 1999-12-28 | Smithkline Beecham Corporation | Pyridyl substituted imidazoles |
EP0624159B1 (en) | 1992-01-13 | 1998-11-25 | Smithkline Beecham Corporation | Pyridyl substituted imidazoles |
MX9300141A (es) | 1992-01-13 | 1994-07-29 | Smithkline Beecham Corp | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
US5716972A (en) | 1993-01-13 | 1998-02-10 | Smithkline Beecham Corporation | Pyridyl substituted imidazoles |
GB9303993D0 (en) | 1993-02-26 | 1993-04-14 | Fujisawa Pharmaceutical Co | New heterocyclic derivatives |
US5593991A (en) | 1993-07-16 | 1997-01-14 | Adams; Jerry L. | Imidazole compounds, use and process of making |
US5593992A (en) | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
US5670527A (en) | 1993-07-16 | 1997-09-23 | Smithkline Beecham Corporation | Pyridyl imidazole compounds and compositions |
IL110296A (en) | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
WO1995003297A1 (en) | 1993-07-21 | 1995-02-02 | Smithkline Beecham Corporation | Imidazoles for treating cytokine mediated disease |
US5869043A (en) | 1993-09-17 | 1999-02-09 | Smithkline Beecham Corporation | Drug binding protein |
DK0724588T3 (da) | 1993-09-17 | 2000-05-15 | Smithkline Beecham Corp | Lægemiddelbindende protein |
US5783664A (en) | 1993-09-17 | 1998-07-21 | Smithkline Beecham Corporation | Cytokine suppressive anit-inflammatory drug binding proteins |
US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
CA2148931A1 (en) | 1993-10-01 | 1995-04-13 | Jurg Zimmermann | Pyrimidineamine derivatives and processes for the preparation thereof |
EP0672041B1 (en) | 1993-10-01 | 2001-11-14 | Novartis AG | Pharmacologically active pyridine derivatives and processes for the preparation thereof |
JP3588116B2 (ja) | 1993-10-01 | 2004-11-10 | ノバルティス アクチェンゲゼルシャフト | 薬理活性のピリミジンアミン誘導体およびその製造方法 |
DE69433501T2 (de) | 1993-11-08 | 2004-11-04 | Smithkline Beecham Corp. | Oxazole zur behandlung von zytokinvermittelten erkrankungen |
US5559137A (en) | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
US5545669A (en) | 1994-06-02 | 1996-08-13 | Adams; Jerry L. | Anti-inflammatory compounds |
WO1996021654A1 (en) | 1995-01-12 | 1996-07-18 | Smithkline Beecham Corporation | Novel compounds |
US5658903A (en) | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US5739143A (en) | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
WO1997005878A1 (en) | 1995-08-10 | 1997-02-20 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
ATE235239T1 (de) | 1995-08-10 | 2003-04-15 | Merck & Co Inc | 2-substituierte aryl-pyrrolen, zusammensetzungen solche verbindungen enthaltend und deren verwendung |
AU702146B2 (en) | 1995-10-06 | 1999-02-11 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
JPH11514651A (ja) | 1995-10-31 | 1999-12-14 | メルク エンド カンパニー インコーポレーテッド | 置換ピリジルピロール、前記化合物を含む組成物及び使用方法 |
AU7529096A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
AU7482396A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
ZA9610687B (en) | 1995-12-22 | 1997-09-29 | Smithkline Beecham Corp | Novel synthesis. |
CN1213306A (zh) | 1996-01-11 | 1999-04-07 | 史密丝克莱恩比彻姆公司 | 新的取代咪唑化合物 |
EP0883402A4 (en) | 1996-01-11 | 1999-08-11 | Smithkline Beecham Corp | NEW CYCLOALKYL-SUBSTITUTED IMIDAZOLES |
AP9700912A0 (en) | 1996-01-11 | 1997-01-31 | Smithkline Beecham Corp | Novel cycloalkyl substituted imidazoles |
ZA97175B (en) | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
US6372741B1 (en) | 1996-03-08 | 2002-04-16 | Smithkline Beecham Corporation | Use of CSAID™ compounds as inhibitors of angiogenesis |
EP0888335A4 (en) | 1996-03-13 | 2002-01-02 | Smithkline Beecham Corp | NEW PYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CYTOKININ MEDIATOR DISEASES |
US6096739A (en) | 1996-03-25 | 2000-08-01 | Smithkline Beecham Corporation | Treatment for CNS injuries |
WO1997035855A1 (en) | 1996-03-25 | 1997-10-02 | Smithkline Beecham Corporation | Novel treatment for cns injuries |
AU727939B2 (en) | 1996-04-03 | 2001-01-04 | Merck & Co., Inc. | A method of treating cancer |
ATE294174T1 (de) | 1996-06-10 | 2005-05-15 | Merck & Co Inc | Substituierte imidazole mit cytokinin- inhibirender wirkung |
KR100371620B1 (ko) | 1996-07-18 | 2003-05-09 | 머크 프로스트 캐나다 앤드 캄파니 | 선택적인 사이클로옥시게나제-2 억제제로서의 치환된 피리딘 |
EP0922042A1 (en) | 1996-08-09 | 1999-06-16 | Smithkline Beecham Corporation | Novel piperazine containing compounds |
WO1998007425A1 (en) | 1996-08-21 | 1998-02-26 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
WO1998016230A1 (en) | 1996-10-17 | 1998-04-23 | Smithkline Beecham Corporation | Methods for reversibly inhibiting myelopoiesis in mammalian tissue |
WO1998022457A1 (en) | 1996-11-19 | 1998-05-28 | Amgen Inc. | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents |
CA2271893A1 (en) | 1996-11-20 | 1998-05-28 | Linda L. Chang | Triaryl substituted imidazoles as glucagon antagonists |
IL130181A0 (en) | 1996-12-05 | 2000-06-01 | Amgen Inc | Substituted pyrimidone and pyridone compounds and methods of use |
ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
WO1998028292A1 (en) | 1996-12-23 | 1998-07-02 | Smithkline Beecham Corporation | Novel piperidine containing compounds |
US5929076A (en) | 1997-01-10 | 1999-07-27 | Smithkline Beecham Corporation | Cycloalkyl substituted imidazoles |
HRP980143A2 (en) | 1997-04-09 | 1999-02-28 | Soo Sung Ko | 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors |
US6362193B1 (en) | 1997-10-08 | 2002-03-26 | Smithkline Beecham Corporation | Cycloalkenyl substituted compounds |
AR017219A1 (es) | 1997-12-19 | 2001-08-22 | Smithkline Beecham Corp | Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento |
AU4429799A (en) * | 1998-06-12 | 1999-12-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
BR9914677A (pt) | 1998-10-23 | 2001-07-17 | Hoffmann La Roche | Heterociclos de nitrogênio bicìclicos |
-
2000
- 2000-11-21 WO PCT/US2000/031874 patent/WO2001038313A1/en active IP Right Grant
- 2000-11-21 AU AU17823/01A patent/AU1782301A/en not_active Abandoned
- 2000-11-21 DE DE60023025T patent/DE60023025T2/de not_active Expired - Lifetime
- 2000-11-21 US US10/129,863 patent/US6982270B1/en not_active Expired - Fee Related
- 2000-11-21 EP EP00980576A patent/EP1233950B1/en not_active Expired - Lifetime
- 2000-11-21 AT AT00980576T patent/ATE305787T1/de not_active IP Right Cessation
- 2000-11-21 JP JP2001540076A patent/JP2003528043A/ja not_active Withdrawn
- 2000-11-21 ES ES00980576T patent/ES2249309T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE60023025T2 (de) | 2006-07-13 |
EP1233950A4 (en) | 2003-03-26 |
EP1233950B1 (en) | 2005-10-05 |
US6982270B1 (en) | 2006-01-03 |
AU1782301A (en) | 2001-06-04 |
EP1233950A1 (en) | 2002-08-28 |
DE60023025D1 (de) | 2006-02-16 |
JP2003528043A (ja) | 2003-09-24 |
ATE305787T1 (de) | 2005-10-15 |
WO2001038313A1 (en) | 2001-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2249309T3 (es) | Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa. | |
DK1070056T3 (da) | Phthalazinon-PDE III/IV-inhibitorer | |
DE69917296D1 (de) | Neue substituierte triazolverbindungen | |
AP2001002172A0 (en) | Substituted pyrazoles as p38 kinase inhibitors | |
DE60315146D1 (de) | Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase | |
AP1246A (en) | Substituted pyrazoles as p38 Kinase inhibitors. | |
DK1000035T3 (da) | Substituerede 6-phenylphenanthridiner | |
TW200608977A (en) | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors | |
DE60020595D1 (de) | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren | |
PT1086096E (pt) | Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4 | |
IS7507A (is) | Ný efnasambönd | |
ATE281439T1 (de) | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren | |
DK1377574T3 (da) | 6-phenylbenzonaphtyridiner | |
ATE374189T1 (de) | Phthalazinon-derivate als pde 4 hemmer | |
TW200503722A (en) | Substituted 7-aza-quinazoline compounds | |
ATE268322T1 (de) | Inhibitoren der tryptase | |
DK1104419T3 (da) | N-substituerede azabicyloheptan-derivater, deres fremstilling og anvendelse | |
PL343848A1 (en) | Novel benzimidazoles and benzoxazoles | |
MY141481A (en) | Substituted pyrazoles as p38 kinase inhibitors | |
UY26980A1 (es) | Nuevos compuestos | |
UY24784A1 (es) | Nuevos compuestos de imidazol sustituidos |